|Bid||63.070 x 200|
|Ask||63.230 x 300|
|Day's Range||60.970 - 68.440|
|52 Week Range||60.970 - 172.750|
|PE Ratio (TTM)||-4.08|
|Earnings Date||Nov 1, 2017 - Nov 6, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||173.35|
The FDA on Thursday issued a safety announcement saying Intercept's liver disease treatment Ocaliva is being dosed incorrectly in some patients.
NEW YORK, NY / ACCESSWIRE / September 22, 2017 / Shares of Akari soared on Thursday after the company announced that it would advance its lead investigational drug, Coversin, after a meeting with the FDA. ...
Intercept Pharmaceuticals Inc NASDAQ/NGS:ICPT